about
Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injuryCoronary microvascular resistance: methods for its quantification in humansOff-line motion correction methods for multi-frame PET data.Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.Quantification of cerebral blood flow in healthy volunteers and type 1 diabetic patients: comparison of MRI arterial spin labeling and [(15)O]H2O positron emission tomography (PET).Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: a head-to-head comparison with ¹⁵O H₂O positron emission tomography.(R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: A PET and CMR study.In vivo assessment of myocardial viability after acute myocardial infarction: A head-to-head comparison of the perfusable tissue index by PET and delayed contrast-enhanced CMR.Quantitative agreement between [(15)O]H2O PET and model free QUASAR MRI-derived cerebral blood flow and arterial blood volume.Impact of scar on water-perfusable tissue index in chronic ischemic heart disease: Evaluation with PET and contrast-enhanced MRI.Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.Stroke volume measurements with first-pass dynamic positron emission tomography: comparison with cardiovascular magnetic resonance.Kinetic models for analysing myocardial [(11)C]palmitate data.Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes.Cardiac PET-CT: advanced hybrid imaging for the detection of coronary artery disease.Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritisPulmonary 2-deoxy-2-[(18)F]-fluoro-d-glucose uptake is low in treated patients with idiopathic pulmonary arterial hypertensionRelation of coronary microvascular dysfunction in hypertrophic cardiomyopathy to contractile dysfunction independent from myocardial injury.Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy.Feasibility of subendocardial and subepicardial myocardial perfusion measurements in healthy normals with (15)O-labeled water and positron emission tomographyPartial volume correction strategies for quantitative FDG PET in oncology.Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.Prediction of functional recovery after revascularization in patients with chronic ischemic myocardial dysfunction: perfusable tissue index by positron emission tomography and contrast-enhanced MRI comparison study.Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion.In vivo validation of reconstruction-based resolution recovery for human brain studies.PET/SPECT: functional imaging beyond flow.Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism.Parametric imaging of myocardial viability using ¹⁵O-labelled water and PET/CT: comparison with late gadolinium-enhanced CMRCerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age.Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.Consensus nomenclature for in vivo imaging of reversibly binding radioligands.Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scannerMeasuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.Neurophysiological effects of sleep deprivation in healthy adults, a pilot study.Radioligand studies: imaging and quantitative analysis.
P50
Q28243395-23DCE732-0B1B-4F2D-9E75-6738845C8790Q30487553-75282D6E-526C-4E9B-9A4F-00D408853001Q30491744-1B326B83-36A7-4339-A69F-06876B2A565AQ30645097-1E56FD80-6A46-4939-B4F2-B8DF2EDF5E0EQ30692074-1107C0AB-7D0A-40FA-B672-8793FB243B15Q30757748-B595C83B-0BCC-48DA-83F6-7FF029220471Q30993837-148D808E-3DE7-4358-A993-EBBD25A681A5Q31020513-AB178A99-0D6E-49A2-A5F1-0F3323C3434DQ31042856-88481C90-5408-42EB-8205-B49D7120F297Q31045631-1F97AAAC-ABD0-4029-B0FF-3EB92BB3F135Q31045880-9883A273-459D-48A2-ACD4-386CEEA10A24Q31049621-4A3FF1DB-0E79-4E5B-BF84-7AD495AA0F72Q31058374-A152B213-AEA6-49F7-8BEB-FD6D87826D22Q31150815-8C11B1AF-3725-40D2-81A2-B1B4906362FEQ33403208-F18AA4C8-3442-49BE-AEE9-E8A6904287E6Q33629852-ED16FF8C-2303-429C-A38D-055839041E0EQ33688206-01C2E1DB-7604-4872-A15A-FF1782143407Q33708984-44DD0F3A-B40D-41AC-8540-79C1553A1133Q33767010-40713CE5-94A9-4634-AE69-059E18157DF8Q33806143-CA916FEC-9D2F-4CE6-9074-CEC238D2D9C2Q33837863-4B3626D5-37D8-4059-86CB-48141BB3EF27Q33872015-C0E47C95-CC00-458E-A0C0-C956E85FB63EQ33881928-C010199A-350F-4647-9B2A-C33446F15DCEQ34054615-875296A0-3C2E-41D5-A817-F621B6A00848Q34054904-F97D2BE1-BE1A-4C84-B86F-293EDD6AD898Q34063955-8502E50E-8423-46EB-BC02-27684933E8C6Q34102506-DB176141-5F80-4B11-AEFD-08B3FA6D271BQ34170769-F5016114-6E0C-4F8B-BC68-B4E0DDFA3375Q34170801-C1C6F35C-C4DA-4262-B4A7-FB1AF0100944Q34232154-F8661B51-F678-4498-99B0-21A1626E6A80Q34237602-31B73FA7-D70C-48EF-BA1C-AEBE3E24CF70Q34265956-CD893D8E-42A8-4767-AF30-D9F62818CAF2Q34302941-C22F9B8E-4708-42FC-A594-847819E1C73EQ34544677-C2FA29A8-FA41-44A5-A587-D27D0AD53FDDQ34630958-D5A30FAE-CEC7-4560-8CCA-1440674483F5Q34757040-C3587F6E-927C-4394-8B0E-2A71542BE765Q34757048-E194BA3C-3D3B-413F-A6FE-8B561DF71DB4Q34860276-74D03BDF-BDF8-4271-9B46-2A9D91D7FAA3Q34995321-FD8C1675-B0E0-49D1-B8CB-59D650FE7285Q35017887-A474AD99-AB59-43D7-870F-196C90E197F0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adriaan A Lammertsma
@ast
Adriaan A Lammertsma
@en
Adriaan A Lammertsma
@es
Adriaan A Lammertsma
@nl
Adriaan A Lammertsma
@sl
type
label
Adriaan A Lammertsma
@ast
Adriaan A Lammertsma
@en
Adriaan A Lammertsma
@es
Adriaan A Lammertsma
@nl
Adriaan A Lammertsma
@sl
altLabel
Adriaan A. Lammertsma
@en
prefLabel
Adriaan A Lammertsma
@ast
Adriaan A Lammertsma
@en
Adriaan A Lammertsma
@es
Adriaan A Lammertsma
@nl
Adriaan A Lammertsma
@sl
P106
P1153
7005884819
P21
P2456
P2798
P31
P496
0000-0003-1237-2891